Rohan Prasad
Research Subjects
Rohan Prasad has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Abdelrahman Ibrahim Abushouk
Section of Cardiovascular Imaging, Department of Cardiovascular Medicine (T.D., E.H., A.D.A., R.K., J.E.D., A. Agrawal, Y.O., D.M., K.B., U.S., M.A., A. Abushouk, A.B., S.H., Z.P., L.L.R., B.G., T.K.M.W.), Heart, Vascular and Thoracic Institute, Cleveland Clinic, OH
2 shared publications Agam Bansal
Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland, Ohio, USA
2 shared publications- Daniel Pastel
Cleveland Clinic Akron General, Department of Internal Medicine, Akron, OH 44307, USA
2 shared publications - Faiz Anwer
Cleveland Clinic, Cleveland, USA
2 shared publications - Grant William Reed
Cleveland Clinic
2 shared publications - Jack Khouri
Cleveland Clinic, Cleveland, USA
2 shared publications
Latest Publications
- Open Access
- 21 June 2025
- Published by Elsevier in Structural Heart
- Vol. 9 (9) , 100686
Neo-Sinus Washout Time Following Transcatheter Aortic Valve Replacement and Hemodynamic Outcomes
- 21 June 2025
- Published by Elsevier in Structural Heart
- Vol. 9 (9) , 100686
Open AccessNeo-Sinus Washout Time Following Transcatheter Aortic Valve Replacement and Hemodynamic Outcomes
- 1 May 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (5) , e014532
Valve-in-Valve TAVR in Patients With Failed Trifecta Bioprosthetic Aortic Valves
- 1 May 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (5) , e014532
Valve-in-Valve TAVR in Patients With Failed Trifecta Bioprosthetic Aortic Valves
- Open Access
- 29 September 2024
- Published by MDPI AG in Antibodies
- Vol. 13 (4) , 80
Insights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma
Multiple myeloma (MM) is a hematological malignancy and poses significant therapeutic challenges. This review synthesizes evidence from pivotal clinical trials to guide induction treatment for transplant-eligible (TE), newly diagnosed MM (NDMM) patients. Emphasizing the evolution from three-drug to four-drug induction therapies, we highlight the integration of monoclonal antibodies, particularly CD38 recombinant monoclonal antibody agents, into treatment regimens. This analysis includes a comprehensive literature review of research from major databases and conferences conducted between 2010 and 2023, culminating in the detailed evaluation of 47 studies. The findings underscore the superiority of quadruple regimens in TE NDMM, notably those incorporating daratumumab, in achieving superior responses including progression-free survival (PFS), minimal residual disease (MRD) negativity, objective response rate (ORR), and overall survival (OS) when compared to triple-drug regimens. As treatment regimens evolve with additional agents, the improved outcomes with treatment-related adverse events should be carefully balanced. This review advocates for a paradigm shift towards quadruple induction therapies for TE NDMM, offers a detailed insight into the current landscape of MM treatment, and reinforces a new standard of care.
- 29 September 2024
- Published by MDPI AG in Antibodies
- Vol. 13 (4) , 80
Open AccessInsights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma
Multiple myeloma (MM) is a hematological malignancy and poses significant therapeutic challenges. This review synthesizes evidence from pivotal clinical trials to guide induction treatment for transplant-eligible (TE), newly diagnosed MM (NDMM) patients. Emphasizing the evolution from three-drug to four-drug induction therapies, we highlight the integration of monoclonal antibodies, particularly CD38 recombinant monoclonal antibody agents, into treatment regimens. This analysis includes a comprehensive literature review of research from major databases and conferences conducted between 2010 and 2023, culminating in the detailed evaluation of 47 studies. The findings underscore the superiority of quadruple regimens in TE NDMM, notably those incorporating daratumumab, in achieving superior responses including progression-free survival (PFS), minimal residual disease (MRD) negativity, objective response rate (ORR), and overall survival (OS) when compared to triple-drug regimens. As treatment regimens evolve with additional agents, the improved outcomes with treatment-related adverse events should be carefully balanced. This review advocates for a paradigm shift towards quadruple induction therapies for TE NDMM, offers a detailed insight into the current landscape of MM treatment, and reinforces a new standard of care.
- Open Access
- 17 September 2024
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 33 (11) , e55-e56
Giant Recurrent Left Ventricular Pseudo-Aneurysm
- 17 September 2024
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 33 (11) , e55-e56
Open AccessGiant Recurrent Left Ventricular Pseudo-Aneurysm
- Open Access
- 19 August 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 35 (10) , 2076-2080
Cardioneuroablation can be an effective strategy to treat glossopharyngeal neuralgia‐related sinus bradycardia and pauses
Introduction: Cardioneuroablation (CNA) has proven effectiveness in addressing hypervagotonia symptoms, such as neurocardiogenic syncope.Methods and Results: In this case, we present the first‐time application of CNA in a case of vago‐glossopharyngeal neuralgia (VGPN). A 59‐year‐old female with near‐syncope, sinus bradycardia, and sinus pauses triggered by recurrent right‐sided neck pain was diagnosed with VGPN. The patient underwent successful treatment with carbamazepine and CNA. Subsequent follow‐up revealed the sustained absence of sinus bradycardia or pauses, even upon neck pain resurgence after discontinuing carbamazepine.Conclusion: In this patient, CNA successfully prevented pauses associated with VGPN, avoiding permanent pacemaker implantation.
- 19 August 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 35 (10) , 2076-2080
Open AccessCardioneuroablation can be an effective strategy to treat glossopharyngeal neuralgia‐related sinus bradycardia and pauses
Introduction: Cardioneuroablation (CNA) has proven effectiveness in addressing hypervagotonia symptoms, such as neurocardiogenic syncope.Methods and Results: In this case, we present the first‐time application of CNA in a case of vago‐glossopharyngeal neuralgia (VGPN). A 59‐year‐old female with near‐syncope, sinus bradycardia, and sinus pauses triggered by recurrent right‐sided neck pain was diagnosed with VGPN. The patient underwent successful treatment with carbamazepine and CNA. Subsequent follow‐up revealed the sustained absence of sinus bradycardia or pauses, even upon neck pain resurgence after discontinuing carbamazepine.Conclusion: In this patient, CNA successfully prevented pauses associated with VGPN, avoiding permanent pacemaker implantation.
- Open Access
- 14 August 2024
- Published by MDPI AG in Preprints.org
Insights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma
Multiple Myeloma (MM), is a hematological malignancy and poses significant therapeutic challenges. This review synthesizes evidence from pivotal clinical trials to guide induction treatment for transplant-eligible (TE), newly diagnosed MM (NDMM) patients. Emphasizing the evolution from three-drug to four-drug induction therapies, we highlight the integration of monoclonal antibodies, particularly CD38 recombinant monoclonal antibody agents, into treatment regimens. Our analysis includes a comprehensive literature review of research from major databases and conferences conducted between 2010 and 2024, culminating in the detailed evaluation of 47 studies. The findings underscore the superiority of quadruple regimens in TE NDMM, notably those incorporating daratumumab, in achieving superior responses including progression-free survival (PFS), minimal residual disease (MRD) negativity, overall response rate (ORR), and overall survival (OS) when compared to triple-drug regimens. As treatment regimens evolve with additional agents, the improved outcomes with treatment-related adverse events should be carefully balanced. This review advocates for a paradigm shift towards quadruple induction therapies for TE NDMM, offers a detailed insight into the current landscape of MM treatment, and reinforces a new standard of care.
- 14 August 2024
- Published by MDPI AG in Preprints.org
Open AccessInsights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma
Multiple Myeloma (MM), is a hematological malignancy and poses significant therapeutic challenges. This review synthesizes evidence from pivotal clinical trials to guide induction treatment for transplant-eligible (TE), newly diagnosed MM (NDMM) patients. Emphasizing the evolution from three-drug to four-drug induction therapies, we highlight the integration of monoclonal antibodies, particularly CD38 recombinant monoclonal antibody agents, into treatment regimens. Our analysis includes a comprehensive literature review of research from major databases and conferences conducted between 2010 and 2024, culminating in the detailed evaluation of 47 studies. The findings underscore the superiority of quadruple regimens in TE NDMM, notably those incorporating daratumumab, in achieving superior responses including progression-free survival (PFS), minimal residual disease (MRD) negativity, overall response rate (ORR), and overall survival (OS) when compared to triple-drug regimens. As treatment regimens evolve with additional agents, the improved outcomes with treatment-related adverse events should be carefully balanced. This review advocates for a paradigm shift towards quadruple induction therapies for TE NDMM, offers a detailed insight into the current landscape of MM treatment, and reinforces a new standard of care.